- 1 Number of words in the Abstract: 150
- 2 Number of words in the Introduction: 508
- 3 Number of words in the Discussion: 1156
- 4 Number of figures: 1
- 5 Number of tables: 3
- 6
- 7 Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on
- 8 biomarker and safety outcomes: systematic review, frequentist and Bayesian
- 9 network meta-analyses
- 10 Danko Jeremic, PhD, Juan D. Navarro-López[†], PhD, Lydia Jiménez-Díaz[†], PhD
- 11 [†]These authors share last senior and corresponding authorship.
- 12
- 13 NeuroPhysiology & Behavior Lab, Institute of Biomedicine (IB-UCLM), School of
- 14 Medicine of Ciudad Real, 13005, University of Castilla-La Mancha, Spain.
- 15
- 16 *Correspondence to:
- 17 J.D. Navarro-Lopez and L. Jimenez-Diaz
- 18 Neurophysiology and Behavior Lab
- 19 Universidad Castilla-La Mancha
- 20 13071-Ciudad Real
- 21 Phone: + 34-926295300 ext 6838
- 22 Fax: + 34-926295300
- 23 E-mail: Juan.Navarro@uclm.es; Lydia.Jimenez@uclm.es
- 24
- 25 Keywords: Network Meta-Analysis; Bayesian; Frequentist; Alzheimer's; Anti-amyloid;
- 26 Aducanumab; Lecanemab; Donanemab;

27 ABSTRACT

28

29 INTRODUCTION

Questions remain regarding safety and clinical relevance of anti-amyloid antibodies in
Alzheimer's disease (AD), with no scientific basis for choosing between different

32 therapies.

33 METHODS

34 Systematic review, frequentist and Bayesian network meta-analyses of phase III

35 randomized placebo-controlled trials were performed to comparatively evaluate

36 cognitive, functional and biomarker efficacy and safety of anti-amyloid antibodies in

37 sporadic AD. Treatments were ranked with P- and SUCRA scores, with rank robustness

measured by Cohen's *kappa*, and uncertainty in ranking probabilities estimated with

39 Shannon's normalized entropy.

40 **RESULTS**

Based on data from 16,971 patients (16 studies), we found Donanemab the best-ranked
antibody on cognitive measures. Lecanemab was the most effective at reducing amyloid
burden. Caution is needed concerning brain edema and microbleeding, with clinically
important risks for Donanemab, Aducanumab and Lecanemab.

45 **DISCUSSION**

46 Risk/benefit profile of anti-amyloid antibodies remains unfavorable. Patients in

47 Donanemab study were stratified by *tau* load, with greater effects observed in

48 low/medium *tau* population.

50 Highlights

51	٠	No single therapy ranked the best among all outcomes.
52	•	Donanemab was the most effective antibody at reducing cognitive decline across
53		all primary outcomes, while Lecanemab ranked the highest on amyloid PET
54		removal.
55	•	Consistently greater cognitive, functional and biomarker effects of Donanemab
56		were observed in patients with low/medium tau load, suggesting more promising
57		effects in earlier AD stages.
58	•	All antibodies, except Solanezumab, were significantly less tolerable than
59		Placebo.
60	•	The risk of cerebral edema and microbleeding may outweigh the benefits,
61		independently of APOE status.
62		

63 1. BACKGROUND

64	Although known for a little more than a century, Alzheimer's disease (AD) became a
65	real-world problem in the last few decades as the most common form of dementia and
66	significant burden for our societies [1]. Until recently, symptomatic treatments were the
67	only therapies available for AD patients, and that situation remains in the majority of
68	countries in the world. The recent approvals of Aducanumab (Aduhelm [®] , U.S) and
69	Lecanemab (Leqembi [®] , U.S and Japan) have initiated the new era in AD therapeutics,
70	as these monoclonal antibodies have shown some potential to modify disease
71	progression by binding to amyloid- β (A β) peptide, toxic peptides thought to be essential
72	in the AD pathophysiology [2]. Both Aducanumab (epitope: 3-7) and Lecanemab
73	(epitope: 1–16) have high selectivity for N-terminus of full-length A β found in soluble
74	oligomers and fibrils, however, Lecanemab showed tenfold stronger binding to small
75	and large protofibrils than to fibrils [3, 4].
76	The regulatory approvals of Aduhelm [®] and Leqembi [®] were both promising and
77	controversial, and they came after more than a decade of investigating anti-A β vaccines
78	and antibodies in AD patients [5, 6]. Many other antibodies, such as Solanezumab
79	(specific to $A\beta$ monomers) and Bapineuzumab (non-specific) were discontinued since
80	they failed to show beneficial effects in clinical trials. Another anti-A β antibody,
81	Donanemab, have gained significant attention recently and it is currently under review
82	for standard approval in the EU and the U.S. Instead of binding the N-terminus of full-
83	length A β , Donanemab targets the N-truncated pyroglutamate A β (at position 3), present
84	only in A β plaques. It is reported to rapidly induce plaque removal and reduce cognitive
85	decline in patients with early symptomatic AD [7, 8].
86	Despite clear advantages of disease-modifying therapies, substantial doubt remains

87 about both the clinical relevance and safety of anti-amyloid antibodies, and they still

have to demonstrate clinically meaningful effect in real life [9, 10]. We have previously 88 89 conducted the systematic review and web application meta-analysis of anti-Aß antibodies in phase III randomized placebo-controlled clinical trials (RCTs), showing 90 that Aducanumab and Lecanemab produced the most promising biomarker results 91 (reducing both Aß and *tau* load) and improved cognitive outcomes by small effect size 92 when compared to control group. However, these cognitive effects were achieved at the 93 94 great expense of increasing adverse events, most importantly amyloid-related imaging abnormalities (ARIA) in the form of cerebral edema (ARIA-E), hemorrhages and 95 localized superficial siderosis (ARIA-H) [11]. Our study had some limitations, as we 96 97 performed only the conventional (frequentist) meta-analysis method with DerSimonian and Laird random-effect model. This did not allow us to estimate the relative effects and 98 compare the performance of these treatments. Also, we did not analyze amyloid PET 99 100 data from original studies, and we failed to include the effects of Donanemab, as phase III trial results on this drug were not available at the time. Therefore, our aim in this 101 102 study was to update and expand our previous study by conducting random-effect 103 frequentist and Bayesian network meta-analyses (NMAs) of phase III RCTs in order to 104 compare the effects of anti-AB antibodies and rank their performance across cognitive, 105 functional, biomarker and safety outcomes.

107 2. METHODS

- 108 2.1. Search strategy
- 109 We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses
- 110 (PRISMA) NMA guideline of health care interventions [12]. The comprehensive
- search for published phase III trials was done on March 11, 2024, using the following
- 112 keywords: "Alzheimer's", "sporadic", "mild cognitive impairment", "phase 3",
- "monoclonal antibody", "passive immunotherapy", "Aducanumab", "BIIB037",
- 114 "Lecanemab", "BAN-2401", "Solanezumab", "LY2062430", "Bapineuzumab" and
- 115 "AAB-001", "Donanemab" and "LY3002813". The search was performed on Google
- 116 Scholar, PubMed, and clinical trial databases, including International Clinical Trials
- 117 Registry Platform (ICTRP) of the World Health Organization, the U.S. Clinical trial
- 118 Registry Clinical Trials.gov, The EU Clinical Trial Registry and Australian New Zealand
- 119 Clinical Trials Registry (ANZCTR).

120 2.2. Quality assessment

121 Modified Jadad scale was used to assess the methodological quality of clinical trial

122 reports. The Jadad scale, also known as the Oxford quality scoring system has been

- tested for reliability in different settings [13, 14] and includes the evaluation of study
- 124 randomization, blindness of patients and investigators, blindness in outcome
- assessment, report of withdrawals, and dropouts [15]. In addition, we evaluated
- reporting of the methodology used to assess adverse events (most notably ARIA),
- 127 whether ARIA is reported depending on the APOE genotype, and whether the methods
- 128 of the statistical analysis were described in the study. The studies were excluded if they
- 129 (1) had modified Jadad score < 3; (2) were not phase III RCTs; (3) did not include

patients with mild cognitive impairment (MCI) or sporadic AD; (4) tested less than 50
participants for cognitive and safety measures.

132 2.3. Risk of bias

- 133 The potential bias was classified as "low risk", "with some concerns", or "high risk, by
- using Revised Cochrane risk-of-bias tool (RoB 2). The domains encompassed in RoB 2
- analysis cover all types of bias that are currently understood to affect the results of
- 136 RCTs: (1) bias arising from the randomization process; (2) bias due to deviations from
- intended interventions; (3) bias due to missing outcome data; (4) bias in measurement of
- the outcome; and (5) bias in selection of the reported result [16]. Risk-of-bias
- assessments were visualized using RoB 2 web app [17]. Finally, publication bias was
- statistically evaluated for efficacy outcomes with more than ten studies [18] by using
- 141 Egger's regression test [19], funnel plots, and the Duval & Tweedie's Trim-and-Fill
- 142 procedure [20].

143 2.4. Grading the evidence and the impact of COVID-19 pandemic

To evaluate the quality of underlying evidence and the strength of recommendations in 144 145 this study, we followed Grades of Recommendation, Assessment, Development, and 146 Evaluation (GRADE) approach that focuses on six items: within-study bias, reporting 147 bias, indirectness, imprecision, heterogeneity, and incoherence. In addition, the impact of COVID-19 pandemic on each study was evaluated by summarizing the number (%) 148 149 of patients affected by COVID-19 disease (Drug vs. Placebo) and how the pandemic affected each stage of the trial, including adverse events and dropouts, missing doses, 150 delays and staffing difficulties, and whether the impact of COVID-19 was analyzed in 151 the main and sensitivity analyses. 152

Primary outcomes included efficacy measures reported by all or the majority of the

153 2.5. Outcomes

- 155 original studies. These were mean changes from baseline in cognitive function 156 evaluated by AD Assessment Scale-Cognitive Subscale (ADAS-Cog), Clinical 157 Dementia Rating scale-Sum of Boxes (CDR-SB), and Mini Mental State Examination 158 (MMSE). Secondary outcomes were biomarker and safety measures reported by all or the majority 159 160 of studies. Biomarker outcomes included changes from baseline in amyloid burden on PET (centiloid scale), cerebrospinal fluid (CSF) levels of $A\beta_{1-42}$ and p-tau (Thr₁₈₁), and 161 plasma *p-tau*. Safety measures were Serious adverse events, tolerability (treatment 162 163 discontinuations due to adverse events), total events of ARIA-E (cerebral edema), cerebral microhemorrhages, total events of ARIA-H (including cerebral 164 165 microhemorrhages, macrohemorrhages and superficial siderosis), headaches, fatigue, 166 dizziness, syncope, nausea, falls, cardiac disorders, back pain, arthralgia,
- 167 nasopharyngitis, upper respiratory and urinary infections.
- 168 Tertiary outcomes included efficacy and safety measures reported by few studies only:
- 169 functional scale AD Cooperative Study-Activities of Daily Living in MCI (ADCS-
- 170 ADL-MCI), superficial siderosis (ARIA-H), infusion-related reactions and total events
- of ARIA-E and ARIA-H in APOE-ε4 non-carriers and carriers (total and depending on
 the ε4 allele dose).
- 173 The results of NMAs were summarized by League Tables with Standardized Mean
- 174 Differences (SMDs) calculated for efficacy (continuous) outcomes, and Relative Risks
- 175 (natural logarithm) for safety outcomes.

176 2.6. Data analysis and reporting

177	The aims of this study were to: (1) update our previous study by performing		
178	conventional (frequentist) random-effect meta-analysis with DerSimonian and Laird		
179	od and (2) conduct frequentist and Bayesian NMA to assess comparative efficacy		
180	and safety of anti-amyloid antibodies. The results obtained from different methods were		
181	then compared for each outcome. In order to properly manage the differences among		
182	multiple subgroups within the primary studies with respect to differences in drug doses,		
183	biomarker findings and other patient characteristics, we followed the recommendation		
184	to treat each subgroup as a separate study [21].		
185	2.6.1. Frequentist NMA		
186	Frequentist random-effects NMA was conducted using the <i>netmeta</i> package [22] in R		
187	(version 4.2.2). The values of I^2 statistic and their statistical significance were evaluated		
188	for overall heterogeneity or inconsistency in the network, which was then split into		
189	within-design (i.e., heterogeneity) and between-design (i.e., inconsistency) and the		
190	statistical significance of Q-values was assessed. For each outcome, the results are		
191	presented in the form of league tables and treatment rankings calculated as P-scores by		
192	using netrank function from netmeta package [22-24]. P-score of 1 is the best possible		
193	score and 0 is the worst. Further information on this ranking can be found in the Method		
194	section of the Supplement.		
195	2.6.2. Bayesian NMA		

196 Bayesian random-effect NMA was performed by using *rjags* and *gemtc* packages in R

- 197 [25] and JAGS 4.3.0 software [26] that allow automating NMA in the Bayesian
- 198 hierarchical model framework with uninformative priors and Markov chain Monte
- 199 Carlo (MCMC) estimation. The number of tuning iterations was set at 10 and the

number of simulation iterations at 100,000. Convergence of the MCMC model was 200 201 assessed through Gelman-Rubin plots and the potential scale reduction factor. Trace and density plots were then applied to determine the best parameters of the number of burn-202 203 in iterations, the number actual simulation iterations, and thinning parameter. For each outcome, the results are presented in the form of league tables and rankings are 204 205 calculated in the form of SUCRA score (surface under the cumulative ranking curve). 206 This score can be interpreted as the estimated proportion of treatments worse than the treatment of interest ($0\% \le SUCRA \le 100\%$). Values of SUCRA close to 1 (100%) 207 indicate the higher likelihood that specific treatment is the best. To calculate the 208 209 SUCRA scores in R, we used the sucra function from dmetar package in R [23]. Further information on SUCRA score can be found in the Supplement. 210

211 2.6.3. Influence and Sensitivity Analyses

212 Influence analyses were done to detect outliers and influential studies in the network.

213 These included heterogeneity assessments using Baujat plots, Influence diagnostics, and

Leave-One-Out meta-analysis. Then, graphic display of study heterogeneity (GOSH)

215 plot analysis was used to examine the results of an equal-effects model in the

combinatorial meta-analyses with all possible subsets of studies [23, 27]. GOSH plot

217 diagnostics employs three unsupervised machine learning algorithms: (1) k-means

clustering based on vector quantization [28], (2) density-based spatial clustering of

applications with noise (DBSCAN) [29], and (3) probabilistic Gaussian mixture model

220 (GMM) [30]. Sensitivity analyses were then performed by rerunning frequentist and

221 Bayesian NMAs upon excluding influential observations.

222 2.6.4. Rank Robustness

223 To quantify the influence a study had on the SUCRA based treatment ranks, the

robustness of ranks was evaluated within the sensitivity analyses, upon excluding all 224 225 influential studies and during Leave-One-Out meta-analysis. The influence of study 226 elimination on the ranks in the Bayesian NMA was estimated by using quadratic 227 weighted Cohen's kappa [31], as recently proposed by Daly and colleagues [32]. This 228 allowed us to measure the agreement between the ranks produced with the complete dataset and the ranks produced from sub-datasets generated upon removing influential 229 230 studies and each study at a time. The magnitude of Cohen's kappa is usually categorised into levels of agreement for interpretation (eg, poor (<0%), slight (0%-20%), fair 231 (21%40%), moderate (41%-60%), substantial (61%-80%) and almost perfect (81%-232 233 100%) agreement). However, it should be added that a kappa is not an index of accuracy but of agreement beyond chance [33], and that the uncertainty of rankings and other 234 235 study characteristics that are context-dependent should be incorporated into the 236 interpretation of the results, as a kappa value of 90%, for example, is not always indicative of almost perfect rank agreement [32]. The calculations were performed by 237 238 using cohen.kappa function available in psych package in R [34]. In addition, the robustness of each rank was examined by determining how many (%) studies did not 239 240 change any treatment rank (%), as well as how many (%) studies displaced treatment 241 ranks.

242 2.6.5. Rank Uncertainty

The uncertainty of the SUCRA ranks in Bayesian NMA is visualized by rankograms and tables that show the distribution of the ranking probabilities [35-37], as suggested by the PRISMA–NMA guideline and GRADE working group. Furthermore, we measured Shannon's information entropy, as recommended recently by Wu et al (2021) [38]. The authors suggested very intuitive way to estimate uncertainty associated with ranking probabilities in NMA by applying Shannon's information entropy formula to obtain a

normalised entropy score. Their work showed that the normalised entropy score gives a 249 250 more accurate assessment of ranking uncertainty and does not depend on the number of 251 analysed treatments. This approach can be used to compare the uncertainty of treatment rankings within a NMA and also between different NMAs, which is crucial for 252 interpretation of results [38]. 253 254 For a NMA, the most precise scenario would be that we are absolutely certain in the 255 ranking of treatments in our network. Therefore, each treatment would have 100% probability of being in one ranking position and 0% probability for the other positions 256 (peaked distribution). Under this scenario, the entropy is zero bit, and Shannon's 257 258 normalized entropy equals zero. On the other hand, the normalized entropy reaches 1 in the least precise scenario when the ranking probabilities are the same for each rank (flat 259 distribution). In this work, we regarded as "low" those values of normalized entropy 260 that were equal or lower than 0.25 and "moderate" those between 0.25 and 0.5. Larger 261 values were considered as conveying "high" or "substantial" uncertainty or normalized 262 263 entropy associated with ranking probabilities. Further information on normalized entropy score, and the code for calculation are located in the Supplement. 264

265 2.6.6. Clinical relevance

Finally, the clinical relevance of the statistically significant results (compared to 266 267 Placebo) from the frequentist main NMA and sensitivity analyses was assessed by 268 calculating the "Number Needed to Treat" (NNT) or "Number Needed to Harm" (NNH) from the treatment's pooled effect size (Hedges g') by Area Under the Curve (AUC) 269 270 method [39]. Here, AUC is defined as the probability that a patient receiving the 271 treatment has an outcome preferable to one receiving Placebo. Lower NNT and higher 272 NNH values are associated with a more favorable benefit/risk profile. The best NNT is 1, indicating that for every patient treated one got better, while NNT > 1, means that the 273

fewer people will benefit the treatment [23]. Similarly, NNH of 1 means that for every
patient treated one got harmed, while NNH > 1 suggests that fewer people will be
harmed.

277 **2. RESULTS**

278 The results obtained from the conventional (frequentist) meta-analysis with

279 DerSimonian-Laird estimator were very similar to the Frequentist and Bayesian NMA

results. Due to word limitation and large consistency in the findings, this manuscript

will only refer to the results obtained from the NMAs. Conventional meta-analysis will

be reproducible online in AlzMeta.app (<u>https://alzmetaapp.shinyapps.io/alzmeta/</u>), upon

283 publication of this work.

284 The meta-analysis included 16 studies (11 ClinicalTrials.gov registries), considering

285 different subgroups within certain RCTs as separate studies, according to our

methodology [21]. Bapineuzumab was tested in six studies [40, 41], Solanezumab in

three studies [42, 43] Aducanumab in four studies ([44]), Donanemab in two studies

288 (low/medium-tau and high-tau populations from TRAILBLAZER-ALZ 2 [8], and

Lecanemab in one study [45]. The details concerning the quality of reports from

290 primary studies (modified Jadad scale) can be found in the Supplement (Supplementary

Tables A1 and A2), as well as the number of records identified, included and excluded,

and the overall reasons for exclusions (PRISMA Flow Diagram, Supplement), along

293 with PRISMA Checklist (Supplement). Specific reasons for excluding each primary

study are listed in Supplementary Tables A3 and A4 (Supplement).

In total, 16,971 patients were analyzed in the primary studies, 8,447 (mean age 71,43

296 years) received Placebo, while 8,524 (mean age 71,87) were passively immunized

against A β . All treatments lasted either 76 or 78 weeks across multiple centers, with the

298	average number of trial sites 212.27 (median 198). Acetylcholinesterase inhibitors and		
299	antine were allowed during the trials, alone or in combination. Additional baseline		
300	participant characteristics and the inclusion criteria for primary studies are documented		
301	in the Supplement (Table A5 and A6).		
302	Statistical power was 100% assuming moderate between-studies heterogeneity and any		
303	possible effect size (small, medium, large) (Fig. S1, Supplement). Regarding risk of		
304	hias all studies were considered as either "low risk" or raising "some concerns" (Fig		
504	bias, an studies were considered as entier fow fisk of faising some concerns (11g.		
305	S2a,b and Table A7; Supplement). For each outcome, certainty of evidence is rated low		
306	or very low within each comparison, according to GRADE approach (Table A8;		
307	Supplement), with low number of studies being the most important reason for		
308	downgrading the certainty.		

309 2.1. Primary outcomes

Frequentist NMA results showed that Donanemab, Lecanemab and Aducanumab were 310 311 significantly more effective than Placebo on ADAS-Cog (cognitive scale, Table 1A). Bapineuzumab and Solanezumab had no favorable effects, with frequentist (but not 312 Bayesian) NMA results suggesting that Placebo was superior to Solanezumab on this 313 314 scale. In frequentist framework, Donanemab was significantly more effective than Bapineuzumab and Solanezumab and had a double effect size compared to that 315 316 achieved with Aducanumab and Lecanemab. Bayesian NMA results revealed strong 317 evidence that Aducanumab and Donanemab improved ADAS-Cog and the lack of convincing support for the effects of Lecanemab. Furthermore, in Bayesian framework, 318 we found strong indication that Donanemab outperformed Bapineuzumab, but not 319 320 Solanezumab, which was clear from the credible intervals including zero (Table 1B).

321	ven better results were obtained on cognitive and functional (global) scale CDR-SB		
322	(Table 1C), where Donanemab, Lecanemab and Aducanumab were significantly more		
323	effective than Placebo. Donanemab was more effective than other interventions with		
324	nearly three times greater effect size than that of the approved antibodies. Aducanumab		
325	and Lecanemab were significantly more effective than Bapineuzumab, however, with		
326	the confidence intervals very close to zero. Bayesian NMA produced very similar		
327	results as frequentist NMA on CDR-SB, with the exception of three indirect		
328	comparisons (Donanemab vs. Lecanemab; Lecanemab vs Bapineuzumab and		
329	Aducanumab vs Bapineuzumab), where credible intervals included zero, suggesting the		
330	lack of strong evidence for the non-zero effect in these comparisons (Table 1D).		
331	Frequentist NMA results for MMSE (cognitive) score revealed weaker effects of all		
332	drugs in the network, with Donanemab and Solanezumab significantly more effective		
333	than Placebo (MMSE results for Lecanemab were not reported). These results were		
334	fully validated by Bayesian NMA (Table S1; Supplement).		
225	Heterogeneity was not significant for any primary outcome, and inconsistency was not		
222	Theorogeneity was not significant for any primary outcome, and meonsistency was not		
336	assessed because the network did not have a closed loop. We found no evidence of		
337	publication bias, with the Egger's test p-values 0.661, 0.8462, and 0.8929 for ADAS-		
338	Cog, CDR-SB, and MMSE, respectively. Funnel plots were symmetric for all three		
339	outcomes (Fig. S3a-c in the Supplement), and the imputation of potentially "missing		
340	studies" did not change results.		
341	Across all primary outcomes, Donanemab was the best-ranked antibody according to		
342	both frequentist P-scores [24] and SUCRA scores [35] in Bayesian framework. On		
512	com nequentite i scores [21] and so end i scores [55] in Dayesian name work. On		
343	CDR-SB, Donanemab obtained the maximum scores (near 1) and very low Shannon's		
344	normalized (information) entropy score [38]. This suggests high certainty in the ranking		

345 probabilities for Donanemab on CDR-SB. In contrast, on ADAS-Cog and MMSE,

346	SUCRA scores for Donanemab were 0.93 and 0.89 respectively, with moderate
347	uncertainty in the ranking probabilities (Fig. 1C and Table P1 in the Supplement).
348	Donanemab produced clinically the most relevant effects on all primary outcomes in
349	combined low/medium population and high- <i>tau</i> population, with $NNT = 9$ on ADAS-
350	Cog, 6 on CDR-SB and 13 on MMSE. When Donanemab was compared to
351	Aducanumab and Lecanemab, the most striking difference was observed on CDR-SB,
352	with NNT values almost two times higher for Lecanemab (13) and almost three times
353	higher for Aducanumab (18). On ADAS-Cog, Lecanemab and Aducanumab also had
354	high NNT (15). Finally, Solanezumab had high NNT (20) on MMSE, suggesting low
355	clinical relevance of cognitive effects of this drug.

- 356 2.2. Secondary outcomes
- 357 2.2.1. Biomarkers of A β and *tau*

358 Both Frequentist and Bayesian NMA results showed that Lecanemab, Donanemab, and 359 Aducanumab significantly improved clearance of $A\beta$ deposits from brain when compared to Placebo (Table S2.1; Supplement). Lecanemab demonstrated the greatest 360 amyloid-clearance activity on PET and obtained P- and SUCRA scores very close to 1, 361 362 with high certainty (low information entropy) associated with the ranking probabilities (Table P1 in the Supplement). However, despite large effect-sizes, these data should be 363 364 interpreted with caution, as substantial heterogeneity was found between the studies and 365 the number of analyzed trials/patients was small. While frequentist NMA results 366 indicated significant differences between Lecanemab and other antibodies, Bayesian 367 NMA results revealed a lack of strong evidence that Lecanemab outperformed Aducanumab and Donanemab on this outcome. 368

369	Frequentist NMA results revealed that Aducanumab and Lecanemab were significantly
370	superior to Placebo on CSF biomarkers of $A\beta_{1-42}$ and p-181- <i>tau</i> (data for Donanemab
371	were not reported). Aducanumab significantly outperformed Solanezumab on CSF $A\beta$
372	(Table S2.1) and Bapineuzumab on CSF p-tau (Table S2.2.). Bayesian NMA validated
373	the relative effect of Aducanumab on both CSF A β and p- <i>tau</i> , providing strong evidence
374	in favor of positive effects of Aducanumab on these outcomes when compared to
375	Placebo, but not when compared to other drugs. Furthermore, Bayesian NMA results
376	revealed an absence of strong evidence that Lecanemab was superior to Placebo on CSF
377	A β and p- <i>tau</i> . Aducanumab was ranked the best treatment on both CSF biomarkers of
378	A β and p- <i>tau</i> , with SUCRA scores 0.86 and 0.89, respectively, and moderate
379	uncertainty in the ranking probabilities (Table P1; Supplement).
380	As in case with amyloid PET data, these findings should be interpreted carefully, since
381	CSF biomarker analyses were available only for limited number of patients in few
382	studies, and considerable heterogeneity was found for CSF A β (I ² = 68.9% [20.0%;
383	87.9%]; p-value of Q statistics = 0.012), indicating that the true effect size may vary
384	across studies. Heterogeneity was not significant for CSF p-tau (Table S2.2;
385	Supplement), while the analysis of plasma <i>tau</i> biomarkers had to be dropped because of
386	extreme heterogeneity ($I^2 = 99\%$ [98.5%; 99.3%], p < 0.0001) and differences in
387	measured biomarker outcome.
388	All biomarker effects were clinically relevant for Aducanumab, Lecanemab and
389	Donanemab, with NNT values of 1 for the effects on amyloid burden (PET data),
390	indicating that the favorable effect on amyloid removal was accomplished for each
391	treated patient, with each of these antibodies. NNTs for CSF outcomes were also very
392	small (clinically relevant) for Aducanumab and Lecanemab, with NNT = 2 on CSF A β_1 -

393 42 for both antibodies. As for CSF-p-*tau*, the NNT of Aducanumab (3) was somewhat

lower than that of Lecanemab (4), reflecting slightly greater effect of Aducanumab on p-*tau.*

396 2.2.2. Safety outcomes

397 Anti-amyloid antibodies did not increase the risk of serious adverse events (Table S3.1;

398 Supplement). Nevertheless, both the frequentist and Bayesian NMA results provide

399 substantial evidence that high-clearance antibodies (Donanemab, Lecanemab and

400 Aducanumab) were less tolerable than Placebo and Solanezumab since these drugs

401 greatly increased the risk of treatment discontinuation due to adverse events (Table 2).

402 Donanemab was the least tolerable antibody in the network, significantly worse than

403 Bapineuzumab and Aducanumab. Frequentist NMA results revealed considerable risks

404 of discontinuation for Bapineuzumab when compared to Placebo, however, this was not

405 corroborated in Bayesian analysis.

406 Frequentist and Bayesian NMA results provide compelling evidence that Solanezumab

407 was the most tolerable and the safest antibody in terms of ARIAs (Fig. 1C, Table 2).

408 Other antibodies substantially increased the total risk of ARIA-E and the risk of cerebral

409 microhemorrhages (ARIA-H), when compared to Placebo and Solanezumab.

410 Furthermore, Aducanumab, Donanemab and Lecanemab significantly increased the total

411 risk of ARIA-H (including all the events of cerebral superficial siderosis, micro- and

412 macrohemorrhages), when compared to Solanezumab and Placebo (Tables S3.2 and

413 S3.3 in the Supplement)

414 Frequentist NMA on additional safety outcomes showed that Aducanumab significantly

415 increased the risk of headaches (Table S3.4) and falls (Table S3.5; Supplement) when

416 compared to Placebo, however, with confidence intervals very close to zero and

417 substantial heterogeneity between the studies (see 3.6). Further Bayesian NMA revealed

418 lack of conclusive support for these comparisons. Similarly, in Bayesian framework,

- there was an absence of strong evidence that Donanemab increased the risk of nausea in
- 420 high-tau population, when compared to Placebo, whereas frequentist NMA would
- 421 suggest significant difference in risk (Table S3.6; Supplement).
- 422 Further analyses showed that anti-A β did not raise the risks of fatigue, dizziness,
- 423 arthralgia, back pain, cardiac disorders, diarrhea, nor urinary infections more than
- 424 Placebo (Table S3.7-S3.16; Supplement). In addition, we found no improved risk of
- 425 syncope, nasopharyngitis and upper respiratory infections, however, these events were
- 426 not reported for Donanemab and Lecanemab, antibodies tested in clinical trials affected
- 427 by COVID-19 pandemic (see 2.4 section). Heterogeneity was not significant for
- 428 secondary safety outcomes with the exception of risks of headaches and cardiac
- 429 disorders.
- 430 The risks of treatment discontinuation due to adverse events, total ARIA-E, cerebral
- 431 microhemorrhages, and total ARIA-H were all clinically relevant, with NNH values of
- 432 1, which correspond to the situation in which for each patient treated, one exhibited
- 433 treatment-emergent adverse reaction.
- 434 2.3. Tertiary outcomes

```
435 Frequentist NMA of ADCS-MCI-ADL showed that Aducanumab (NNT = 12) and
```

436 Lecanemab (NNT = 10) significantly slowed functional decline by small effect size,

- 437 when compared to Placebo. Bayesian NMA results validated these results for
- 438 Aducanumab, but not for Lecanemab (Table S4.1). The heterogeneity was not
- 439 significant; however, these results should be interpreted with care since they are based
- 440 on four studies with Aducanumab and one study testing Lecanemab. Furthermore,

credible intervals for the relative effects of Aducanumab (vs. Placebo) were very closeto zero, indicating uncertainty in the evidence (also, see 2.4).

- Both frequentist and Bayesian NMA results gave strong support for increased risk of
- 444 superficial siderosis (ARIA-H) in patients treated with Donanemab and Aducanumab,
- 445 when compared to those in control group, while the results for Lecanemab were not
- 446 conclusive. Whereas frequentist NMA results suggested significantly greater risk (p =
- 447 0.001) of superficial siderosis in patients treated with Lecanemab (compared to
- 448 Placebo), Bayesian NMA gave an estimate with overlapping credible intervals,
- suggesting the lack of strong evidence for this comparison (Table S4.2). Even so, the
- 450 risk of superficial siderosis was clinically relevant for Donanemab, Aducanumab and
- 451 Lecanemab, with NNH values of 1 (the least favorable).
- 452 The risk of infusion-related reactions was clinically meaningful (NNH = 1) for
- 453 Donanemab and Lecanemab (not reported for other drugs), significantly higher (p < p
- 454 0.0001) when compared to Placebo. Both the Frequentist and Bayesian NMA results
- 455 provided strong evidence that Donanemab increased the risks of infusion-related
- 456 reactions, with almost two times greater risk than that observed in Lecanemab study
- 457 (Table S4.3 in the Supplement).

458 Having in mind the limited information regarding ARIA-E and ARIA-H depending on

459 the APOE status, frequentist and Bayesian NMAs strongly indicate that all antibodies,

460 except Solanezumab, significantly increased the risk of ARIA-E in both APOE-ε4

- 461 carriers and non-carriers. The results were not that convincing for ARIA-H, where
- 462 smaller risks were observed and frequentist NMA results suggested significant increase
- 463 in risk for Donanemab and Lecanemab in both carriers and non-carriers, which was not
- validated in Bayesian framework. Due to inconclusive findings on ARIAs depending on
- 465 APOE status, we were unable to determine whether the risk of ARIAs increases

substantially with ε 4 allele dose (homozygotes vs. heterozygotes). Overall, the risk of ARIAs was clinically relevant (NNH = 1) independently of APOE status, and the risk generally increased with each ε 4 allele (Tables S4.4-S4.7 in the Supplement). Heterogeneity between the studies could not be assessed due to small numbers of studies.

471 2.4. Sensitivity analyses

Donanemab consistently showed greater cognitive effects in patients with low/medium 472 473 *tau* load than in high-*tau* population (assessed by PET imaging), and removing this 474 study had a big impact on the results, similarly to the greater effect observed for high-475 dose Aducanumab in controversial EMERGE study, as found in our previous meta-476 analysis [46] (Tables S5 and S7 in the Supplement). For this reason, removing these two 477 studies from the NMAs yielded much lower relative effects of these drugs on cognitive measures (when compared to Placebo), with p-values of 0.0502 and 0.5334 on ADAS-478 Cog and 0.1419 and 0.0249 on CDR-SB for Aducanumab and Donanemab, respectively. 479 480 Likewise, excluding study in low/medium-tau population greatly reduced relative effects of Donanemab on MMSE (p = 0.3430), further emphasizing favorable effects of 481 this drug in patients with low/medium *tau*, but not high *tau* burden. Bayesian NMA 482 validated these findings, strongly indicating that CDR-SB score was improved by 483 484 Donanemab (even in high *tau* population), but not by Aducanumab, after excluding 485 controversial EMERGE study. There was lack of strong evidence for improving both ADAS-Cog and MMSE scores neither by Aducanumab nor by Donanemab after 486 removing their influential studies. Furthermore, frequentist NMA results of amyloid 487 488 PET data revealed that both Donanemab and Aducanumab significantly removed amyloid brain burden (Table S7.4), when compared to Placebo. Conversely, the results 489 from Bayesian NMA provided strong evidence supporting the efficacy of Aducanumab, 490

but not Donanemab. In other words, comparatively higher effect of Donanemab was 491 492 obtained in low/medium-tau population, and removing this measurement increased the uncertainty of the evidence, shifting the credible intervals for the relative efficacy of 493 494 Donanemab from (-6.4251; -2.0495) towards (-9.3948; 1.7020). Finally, frequentist NMA results of ADCS-ADL-MCI showed that removing high-dose Aducanumab 495 496 EMERGE trial did not impact the relative effect of this drug when compared to Placebo 497 (Table S7.7). Bayesian NMA weakly favored Aducanumab over Placebo, however, with credible intervals (-0.014; 0.245) including zero. In summary, significant dose-498 499 dependent efficacy of Aducanumab was evident only in EMERGE study, and the 500 relative effects of Donanemab in the main study were largely due to its beneficial effects on AD patients with low/medium tau load. 501 502 Removing the influential studies of Donanemab and Aducanumab reduced ranking scores of these drugs in the network (Figure 1F). On MMSE score, for example, 503 Solanezumab was the best-ranked drug with SUCRA score 0.81, followed by 504 505 Donanemab in high-tau population (0.71). Lecanemab obtained the best score (0.79) on 506 ADAS-Cog, followed by Aducanumab (0.69), and Solanezumab (0.58). Donanemab in 507 high-tau population was the best-ranked treatment only on CDR-SB score (0.91) and 508 fourth-ranked on ADAS-Cog (0.3). Additionally, Lecanemab was better ranked treatment than Aducanumab on CSF-Aβ₁₋₄₂ and ADCS-ADL-MCI, upon excluding the 509 510 influential effects from high-dose Aducanumab in EMERGE study. For efficacy outcomes, the most robust SUCRA scores were obtained for CDR-SB, with 92% of 511 512 agreement with the main analysis (median of observed weighted Cohen's kappa values) 513 and 8 (50%) studies that did not change any treatment rank. The robustness of SUCRA 514 scores further improved upon excluding influential Aducanumab and Donanemab studies, however, the uncertainty in ranking probabilities also increased. The least 515

robust SUCRA scores were found for amyloid burden on PET, which was a direct 516 consequence of small number of studies. Across all efficacy outcomes, the treatments 517 518 moved only one or very rarely two ranks up or down upon excluding each study at a time. Further details on ranking probabilities and their sensitivity analysis can be found 519 520 in the Supplement (Tables P1-P4; Supplement). Clinical relevance of the cognitive and functional effects of Donanemab and 521 522 Aducanumab decreased remarkably upon removing their influential studies, while the 523 biomarker effects on AB and *p-tau* remained clinically relevant with small NNTs. For Donanemab, the NNT was 28 for ADAS-Cog and 18 for MMSE, while NNT for CDR-524 525 SB did not change drastically (NNT = 8), when compared to the main analysis (NNT = 6). In other words, the beneficial effects of Donanemab on cognitive and functional 526 CDR-SB score in patients with high-tau load were still clinically relevant, even if the 527 effects were greater in those with low/medium tau. Aducanumab had higher (less 528 529 favorable) NNTs in sensitivity analysis for ADAS-Cog (21) and CDR-SB (19). 530 The results of sensitivity analyses on safety outcomes were largely consistent with the main analysis. SUCRA scores for treatment discontinuation, risks of ARIA-E and 531 532 ARIA-H were robust to study exclusions, with median weighted Cohen's kappa values 533 above 89%, indicating almost perfect agreement in study ranks between main and 534 sensitivity analysis (Tables P1-P4 in the Supplement). Additionally, there was small statistically significant increase in the risk of headaches for all high-clearance 535 536 antibodies: Aducanumab (p = 0.0001), Donanemab (p = 0.0085), and Lecanemab (p =0.0323), when compared to Placebo (Table S2.9), after excluding two low-dose 537 538 Bapineuzumab studies [41]. These two studies were the source of high heterogeneity in the main analysis, which was detected by Q statistics (p < 0.0001) and Gaussian 539 Mixture Model in GOSH plot analysis (Table S8.1 and Figure S11 in the Supplement). 540

Bayesian NMA validated frequentist NMA results for Aducanumab and Donanemab, suggesting that these antibodies slightly increased the risk of headaches when compared to Placebo and Solanezumab. On the other hand, there was no conclusive evidence that Lecanemab elevated risk of headaches, when compared to Placebo. Additionally, the statistical significance for the risk of falls in Aducanumab studies dropped (p = 0.8785) once we removed ENGAGE studies (Table S8.2 in the Supplement), suggesting that these studies contributed to the observed high risk of falls in the main analysis.

548 2.5. The Impact of COVID-19 pandemic

549 Lecanemab and Donanemab RCTs included in this study were affected by global

550 outbreak of coronavirus – an infectious disease caused by the severe acute respiratory

syndrome. COVID-19 was the most commonly reported adverse event across treatment

groups in Donanemab studies, ocurring in $\sim 17\%$ of patients in all arms. The impact of

pandemic was less severe on Lecanemab study, with the incidence of COVID-19 around

554 7% in experimental and control groups. The pandemic also caused delays in study visits

and assessments in both trials and other difficulties summarized in the Supplement

556 (Table S6).

558 **3. DISCUSSION**

559	This study reveals a complex pattern of evidence supporting the efficacy of
560	Aducanumab, Lecanemab and Donanemab across multiple cognitive, functional and
561	biomarker outcomes. At the same time, the risks of cerebral edema and microbleeding
562	were substantial, suggesting greater harm than benefit. The similarities and the
563	differences between frequentist and Bayesian NMA results presented here strongly
564	emphasize the need for further studies with larger sample sizes and the need to study
565	these antibodies in earlier stages of AD and MCI, and in younger patients with lower $A\beta$
566	and <i>tau</i> load.
567	The inconsistencies between ENGAGE and EMERGE trials revealed here and in our
568	previous study [46] have been discussed in literature ever since these studies were
569	published, as they caused a lot of controversy within the FDA and in the broader

570 community [47]. The Aducanumab provider, in partial collaboration with the FDA,

571 provided two possible explanations for these discrepancies: (1) fewer numbers of

572 patients in the ENGAGE trial receiving higher doses of drug, and (2) ENGAGE trials

573 had more outliers, and removing these outliers in sensitivity analysis gave more

574 compatible dose-dependent beneficial effects [48, 49]. Despite these inconsistencies,

575 Aducanumab received accelerated approval in the U.S. Afterwards, the FDA granted

576 breakthrough status to Lecanemab and Donanemab, in order to speed up their approval

577 [50], which finally resulted in full FDA approval of Lecanemab in the U.S. and more

578 recently in Japan. Furthermore, Lecanemab is currently undergoing regulatory review in

579 the European Union (EU), United Kingdom, South Korea, and Canada, while

580 Donanemab is reviewed in the EU and the U.S [7]. Recent exploratory post hoc

modeling based on phase III RCT of Donanemab suggested that $A\beta$ levels in immunized

582 patients would remain below the positivity threshold for almost 4 years without the

583	treatment. The authors also revealed that greater plaque removal by Donanemab was		
584	associated with slower progression of <i>tau</i> PET and slower clinical decline, but only in		
585	APOE-ɛ4 carriers [51]. In our study, all high-clearance antibodies (Aducanumab,		
586	Donanemab and Lecanemab) produced substantial A β and <i>tau</i> biomarker effects.		
587	Donanemab was the best-ranked treatment across all cognitive measures, while		
588	Lecanemab was the most efficient at reducing amyloid burden on PET. Donanemab		
589	consistently showed better cognitive, functional and biomarker effects in patients with		
590	low/medium tau load, compared to those with high tau. Donanemab produced clinically		
591	relevant cognitive effects in low/medium-tau population on all three primary outcomes,		
592	suggesting greater benefit of Donanemab in earlier AD stages.		
593	Low tolerance and high risk of ARIAs looms over high-clearance anti-A β antibodies.		
594	Our results showed that Donanemab was significantly less safe and less tolerable than		
595	Placebo and Solanezumab, with similar risks of treatment discontinuation and ARIAs as		
596	in Aducanumab and Lecanemab studies. Both frequentist and Bayesian NMA results		
597	from this study imply that the risk of ARIAs associated with the treatment may		
598	outweigh the benefits, independently of APOE status. In summary, our results		
599	demonstrate modest cognitive and substantial biomarker effects of Donanemab,		
600	Lecanemab and Aducanumab, yet with significant trade-off in the form of dose-		
601	dependent cerebral vasogenic edema (ARIA-E), bleeding and hemosiderin deposits		
602	(ARIA-H), which may or may not be symptomatic or serious adverse event. These risks		
603	require careful dose titration and close patient monitoring on Magnetic Resonance		
604	Imaging (MRI), which increases the costs of already expensive treatments [52]. In our		
605	view, additional and comparative studies of these drugs with vascular biomarkers are		
606	needed to evaluate their risk/benefit profile, as well as more anticipatory policies from		
607	regulatory bodies if we were to avoid new controversies as those seen with the FDA		

approval of Aducanumab. Moreover, personalized approach and safer multi-target
therapies in combination with novel biomarkers is expected to effectively mitigate the
AD progression [53].

611 Different mechanisms of actions of these drugs outlined in the Introduction certainly 612 contribute to the differences in their effects and heterogeneity in our networks. However, there is no doubt that Aducanumab, Lecanemab and Donanemab achieved 613 614 great biomarker results and modest cognitive effects in 18 months. Therefore, 615 comparative and longitudinal studies are required to fully disclose the impact of anti-Aß immunotherapy over longer periods of time. Future trials would need to compare the 616 617 effects of anti-A β antibodies in multiple stages of AD and in different populations, as inter-individual differences and comorbidities may be crucial to prevent ARIAs and 618 select patients that could benefit from anti-Aß immunotherapy. The inflammation and 619 620 vascular comorbidities are of special concern, as blood-brain barrier disruption and Aß 621 deposition are central to the development of both AD (with A β deposited in brain 622 parenchyma) and cerebral amyloid angiopathy (with Aβ deposition on blood vessel 623 walls). These two pathologies often co-occur and APOE-ɛ4 status is known to worsen both of them. Risk factors for ARIA are dose-dependent and include receiving anti-Aß 624 625 immunotherapy, anticoagulant and thrombolytic medication, carrying APOE-e4 allele, 626 and history of brain microhemorrhages and stroke [54, 55]. The important limitations of this study are (1) COVID-19 impacted Donanemab and 627

the brain protein *tau*; (3) the effects of antibodies on plasma *tau* biomarkers could not be
evaluated due to excessive between-study heterogeneity and different measures used in

Lecanemab trials, (2) the patients in Donanemab study were stratified by their level of

- 631 primary studies; (4) potential bias might be introduced due to unmasking, since ARIAs
- 632 were the most frequent treatment-emergent adverse events of all drugs except

633	Solan	ezumab, and (5) direct comparison between the antibodies has not been done yet,
634	and o	ur NMA only included studies where treatments were compared with Placebo.
635	NMA	is a statistical method to compare more than two interventions simultaneously by
636	comb	ining direct and indirect evidence. When head-to-head trials are not available, as
637	often	happens in many research fields, indirect comparisons can be made via a common
638	contro	ol arm (Placebo in our case) [56]. Therefore, this study should be viewed as a way
639	to sur	nmarize the results from previous phase III RCTs and provide comparative
640	assess	sment of these drugs based on existing data, until further evidence comes along.
641	The s	ame should be emphasized for the efficacy and safety rankings and their
642	uncer	tainty measures, as clinical decision making should never be based solely on one
643	or two	o measures or studies.
644		
645	4. RE	SEARCH IN CONTEXT
646	1.	Systematic review and meta-analysis: Frequentist and Bayesian network meta-
647		analyses (NMAs) were performed to compare the efficacy and safety of anti-
648		amyloid antibodies in phase III randomized placebo-controlled trials in sporadic
649		AD.
650	2.	Interpretation: Aducanumab, Lecanemab and Donanemab achieved substantial
651		biomarker results and small cognitive effects, and were less tolerable than
652		Placebo and Solanezumab, significantly increasing the risk of ARIAs.
653		Donanemab was the most efficient antibody on the cognitive measures, but it was
654		also the least tolerable, significantly less tolerable than Placebo, Solanezumab,
655		Bapineuzumab and Aducanumab.
656	3.	Future directions: Studying these drugs in earlier stages and in younger patients
657		with lower A β and <i>tau</i> burden might yield better outcome than that observed in

- 658 phase III trials. Since ARIAs are the major adverse events limiting the broad use
- of anti-amyloid antibodies, prevention of vascular damage, better biomarkers and
- safer, personalized treatment options are needed to improve AD treatment.

661

663 ACKNOWLEDGEMENTS

- This work was supported by grants PID2020–115823-GB100 funded by
- 665 MCIN/AEI/10.13039/501100011033, and SBPLY/21/180501/000150 funded by
- 666 JCCM/ERDF A way of making Europe, and 2022-GRIN-34354 grant by
- 667 UCLM/ERDF intramural funding to LJ-D and JDN-L.

668 AUTHORS' CONTRIBUTIONS

- JDNL and LJD were responsible for the initial conceptualization, funding acquisition,
- supervision, and project administration; DJ was responsible for Data curation, Software,
- 671 Formal analysis, visualization and writing the original draft; SD, JDNL and LJD did the
- 672 writing review and editing. All authors read and approved the final manuscript.

673 CONFLICT OF INTEREST STATEMENT

- All authors declare that they have no conflicts of interest. The protocol for this study
- was not previously registered. Author disclosures are available in the Supporting
- 676 Information.
- 677

678 **REFERENCES**

- [1] Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the secondcentury. Sci Transl Med. 2011;3:77sr1.
- [2] Wessels AM, Dennehy EB, Dowsett SA, Dickson SP, Hendrix SB. Meaningful Clinical
 Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the
 Donanemab TRAILBLAZER-ALZ Study Findings. Neurol Clin Pract. 2023;13:e200127.
- 685 [3] Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al.
- Lecanemab, Aducanumab, and Gantenerumab Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's
- 688 Disease. Neurotherapeutics. 2023;20:195-206.
- [4] Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in
 Alzheimer's disease. Neurobiol Dis. 2020;144:105010.
- [5] Prins ND, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies:current status and outlook for the future. Alzheimers Res Ther. 2013;5:56.

[6] Rabinovici GD, La Joie R. Amyloid-Targeting Monoclonal Antibodies for AlzheimerDisease. Jama. 2023;330:507-9.

695 [7] Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal 696 Antibodies for the Treatment of Alzheimer's Disease. BioDrugs. 2024;38:5-22.

[8] Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early
Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Jama. 2023;330:512-27.

[9] Digma LA, Winer JR, Greicius MD. Substantial Doubt Remains about the Efficacy ofAnti-Amyloid Antibodies. J Alzheimers Dis. 2024;97:567-72.

- [10] Lacorte E, Ancidoni A, Zaccaria V, Remoli G, Tariciotti L, Bellomo G, et al. Safety and
 Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and
 Meta-Analysis of Published and Unpublished Clinical Trials. J Alzheimers Dis.
 2022;87:101-29.
- [11] Jeremic D, Navarro-López JD, Jiménez-Díaz L. Efficacy and safety of anti-amyloid-β
 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic
 review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012.
- 709 [12] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The
- PRISMA extension statement for reporting of systematic reviews incorporating network
 meta-analyses of health care interventions: checklist and explanations. Ann Intern Med.
 2015;162:777-84.
- [13] Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the
 quality of randomized trials: reliability of the Jadad scale. Control Clin Trials.
 1999;20:448-52.
- [14] Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess
 the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88:15675.
- [15] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.
 Assessing the quality of reports of randomized clinical trials: is blinding necessary?
 Control Clin Trials. 1996;17:1-12.
- [16] Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a
 randomized trial. Cochrane handbook for systematic reviews of interventions. 2019:20528.
- [17] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
 revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:I4898.
- 727 [18] Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations
- for examining and interpreting funnel plot asymmetry in meta-analyses of randomisedcontrolled trials. Bmj. 2011;343:d4002.
- [19] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by
 a simple, graphical test. Bmj. 1997;315:629-34.
- [20] Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and
 adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-63.
- [21] Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis:John Wiley & Sons; 2021.
- 736 [22] Balduzzi S, Rücker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O,
- 737 et al. netmeta: An R package for network meta-analysis using frequentist methods.
- 738 Journal of Statistical Software. 2023;106:1-40.

- [23] Harrer M, Cuijpers P, Furukawa T, Ebert D. Doing meta-analysis with R: A hands-onguide: Chapman and Hall/CRC; 2021.
- [24] Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis
 works without resampling methods. BMC Med Res Methodol. 2015;15:58.
- [25] van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating
 network meta-analysis. Res Synth Methods. 2012;3:285-99.
- [26] Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs
 sampling. Proceedings of the 3rd international workshop on distributed statistical
 computing: Vienna, Austria; 2003. p. 1-10.
- [27] Olkin I, Dahabreh IJ, Trikalinos TA. GOSH a graphical display of study heterogeneity.
 Res Synth Methods. 2012;3:214-23.
- [28] Hartigan JA, Wong MA. Algorithm AS 136: A k-means clustering algorithm. Journal
 of the royal statistical society series c (applied statistics). 1979;28:100-8.
- [29] Schubert E, Sander J, Ester M, Kriegel HP, Xu X. DBSCAN revisited, revisited: why and
 how you should (still) use DBSCAN. ACM Transactions on Database Systems (TODS).
 2017;42:1-21.
- [30] Fraley C, Raftery AE. Model-based clustering, discriminant analysis, and density
 estimation. Journal of the American statistical Association. 2002;97:611-31.
- [31] Cohen J. Weighted kappa: nominal scale agreement with provision for scaleddisagreement or partial credit. Psychol Bull. 1968;70:213-20.
- [32] Daly CH, Neupane B, Beyene J, Thabane L, Straus SE, Hamid JS. Empirical evaluation
 of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using
 Cohen's kappa. BMJ Open. 2019;9:e024625.
- [33] Foody GM. Explaining the unsuitability of the kappa coefficient in the assessment
 and comparison of the accuracy of thematic maps obtained by image classification.
 Remote sensing of environment. 2020;239:111630.
- [34] Revelle W. An introduction to the psych package: Part I: data entry and datadescription. Northwestern University. 2019.
- [35] Salanti G. Indirect and mixed-treatment comparison, network, or multiple treatments meta-analysis: many names, many benefits, many concerns for the next
 generation evidence synthesis tool. Research synthesis methods. 2012;3:80-97.
- [36] Cipriani G, Ulivi M, Danti S, Lucetti C, Nuti A. Sexual disinhibition and dementia.
 Psychogeriatrics. 2016;16:145-53.
- [37] Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative
 efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments
 meta-analysis. Lancet. 2011;378:1306-15.
- [38] Wu Y-C, Shih M-C, Tu Y-K. Using normalized entropy to measure uncertainty of
 rankings for network meta-analyses. Medical Decision Making. 2021;41:706-13.
- [39] Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinicalresearch and practice. Biol Psychiatry. 2006;59:990-6.
- [40] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3
 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med.
 2014;370:322-33.
- 782 [41] Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al.
- 783 Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized,
- phase 3 trials. Alzheimers Res Ther. 2016;8:18.

- [42] Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of
 solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
- [43] Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of
 Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med.
 2018;378:321-30.
- [44] Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two
 Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev
 Alzheimers Dis. 2022;9:197-210.
- [45] van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in
 Early Alzheimer's Disease. N Engl J Med. 2023;388:9-21.
- 795 [46] Jeremic D, Navarro-López JD, Jiménez-Díaz L. Efficacy and Safety of Anti-Amyloid-β
- 796 Monoclonal Antibodies in Current Alzheimer's Disease Phase III Clinical Trials: A 797 Systematic Review and Interactive Web App-based Meta-Analysis. Ageing Research 798 Reviews. 2023:102012.
- [47] Largent EA, Peterson A, Karlawish J, Lynch HF. Aspiring to Reasonableness in
 Accelerated Approval: Anticipating and Avoiding the Next Aducanumab. Drugs Aging.
 2022;39:389-400.
- [48] Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB.
 Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review. Int J Alzheimers
 Dis. 2022;2022:9343514.
- [49] Kuller LH, Lopez OL. ENGAGE and EMERGE: Truth and consequences? AlzheimersDement. 2021;17:692-5.
- 807 [50] Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data808 and controversies. Drugs Context. 2021;10.
- [51] Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al.
 Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and
 Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol.
 2022;79:1015-24.
- 813 [52] Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and 814 Donanemab for Early Alzheimer Disease in the US. JAMA Neurol. 2022;79:478-87.
- [53] Toups K, Hathaway A, Gordon D, Chung H, Raji C, Boyd A, et al. Precision Medicine
 Approach to Alzheimer's Disease: Successful Pilot Project. J Alzheimers Dis.
 2022;88:1411-21.
- [54] Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR, Jr., Poussaint TY, et al.
 Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics:
- Detection and Reporting Recommendations for Clinical Practice. AJNR Am J Neuroradiol.2022;43:E19-e35.
- 822 [55] Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging
 823 abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784.
- [56] Higgins JP. Cochrane handbook for systematic reviews of interventions version 6.2.
- 825 Cochrane Database Syst Rev. 2021.
- 826

828 **FIGURES**





Figure 1. The results of Bayesian NMA for efficacy and safety of anti-amyloid

antibodies in Alzheimer's disease in phase III randomized placebo-controlled clinical trials $\mathbf{A} \cdot \mathbf{B}$ and \mathbf{C} correspond to the main analysis with all studies included and $\mathbf{D} \cdot \mathbf{F}$

trials. A, B and C correspond to the main analysis with all studies included, and D, E

- and **F** refer to the sensitivity analysis with two influential studies left out: Donanemab
- study in low/medium-tau population and high-dose EMERGE study of Aducanumab. A,
- **D.** Network models with nodes (circles) representing antibodies, and the width of the
- edges or links (k) indicating the number of studies included for each comparison. **B**, **E**.
- 837 Rankogram for global (cognitive and functional) outcome CDR-SB. The Y axis
- represents the probability for each treatment being the best option, second best option,
- third best option etc. (legend). C, F Scatterplots showing jointly the ranking results for
- 840 efficacy and safety of drugs in the network. SUCRA scores were calculated for the main
- efficacy outcomes (X-axes: CDR-SB and ADAS-Cog) and safety measures (Y-axes:
- tolerability and risk of any ARIA-E). Abbreviations: ARIA-E, Amyloid-Related
- 843 Imaging Abnormalities in form of cerebral Edema; CDR-SB, Clinical Dementia Rating
- 844 Sum of Boxes; SUCRA, Surface Under Cumulative RAnking curve.

846 **TABLES**

847

848 Table 1. League tables representing the results of random-effect model Frequentist and Bayesian network meta-analysis (NMA). The values in the tables represent 849 850 Standardized Mean Differences (SMDs) for cognitive outcome Alzheimer's Disease 851 Assessment Scale-Cognitive sub-scale (ADAS-Cog, A, B) and for global (cognitive and 852 functional) outcome Clinical Dementia Rating Sum of Boxes (CDR-SB, C, D). The number below 0 suggests that the drug in the column is superior to the drug in the row. 853 Darker green colors correspond to relatively greater effects, and bolded numbers denote 854 statistical significance (A, C) or strong evidence (B, D). The numbers in parentheses 855 represent confidence intervals (CIs) in Frequentist NMA (A, C) or credible intervals 856 (CrIs) in Bayesian framework (**B**, **D**). Dagger symbol (†) denotes that the interpretation 857 differs considerably between frequentist and Bayesian NMA results, indicating the 858 uncertainty and lack of strong evidence for a non-zero effect. 859

860

 Table 1A. Frequentist Network Meta-Analysis: ADAS-Cog

Aducanuma b					
-0.0960 (-0.1949; 0.003)	Bapineuzu mab				
0.0913 (-0.0444; 0.227)	0.1873 (0.0624; 0.3121)	Donanemab			
-0.0017 (-0.1251; 0.1217)	0.0943 (-0.0171; 0.2057)	-0.0930 (-0.238; 0.052)	Lecanemab		_
-0.1174 * (-0.1968; - 0.038)	-0.0214 (-0.0805; 0.0376)	-0.2087 ** (-0.3187; - 0.0987)	-0.1157 † *** (-0.2101; - 0.0213)	Placebo	
-0.0503 (-0.1502; 0.0497)	0.0457 (-0.039; 0.1304)	-0.1416 † (-0.2672; - 0.0159)	-0.0486 (-0.1609; 0.0637)	0.0671 † **** (0.0064; 0.1278)	Solanezu mab

Statistical significance for Drug vs. Placebo: * p = 0.0038; ** p = 0.0002; *** p = 0.0163; **** p = 0.0303

Heterogeneity $I^2 = 0\%$ [0.0%; 58.3%]; p-value of Q statistics = 0.6985 in heterogeneity (within designs).

Table 1B. Bayesian Network Meta-Analysis: ADAS-Cog

Aducanuma b	
-0.0959	Bapineuzu mab

(-0.2065;					
0.0178)					
0.0853	0.1803				
(-0.068;	(0.0386;	Donanemab			
0.2344)	0.3196)			_	
-0.0025	0.0932	-0.0870			
(-0.1519;	(-0.0461;	(-0.2589;	Lecanemab		
0.1465)	0.2342)	0.0872)			_
-0.1176	-0.0218	-0.2026	-0.1154 †		
(-0.2058; -	(-0.0890;	(-0.3246; -	(-0.2371;	Placebo	
0.0288)	0.0446)	0.0778)	0.0060)		
-0.04958	0.0454	-0.1358 †	-0.0479	0.0676 †	Salanazu
(-0.16684;	(-0.0569;	(-0.2784;	(-0.1905;	(-0.0092;	Solanezu
0.0646)	0.1468)	0.0108)	0.0947)	0.1421)	mao

Table 1C. Frequentist Network Meta-Analysis: CDR-SB

Aducanuma					
-0.1053 † (-0.2073; - 0.0033)	Bapineuzu mab				
0.2046	0.3099				
(0.0622;	(0.1791;	Donanemab			
0.3471)	0.4407)				
0.0357	0.1409 †	-0.1690 †			
(-0.0977;	(0.0202;	(-0.3255; -	Lecanemab		
0.1690)	0.2617)	0.0125)			
-0.1004 *	0.0048	-0.3051 **	-0.1361 ***		
(-0.1829; -	(-0.0552;	(-0.4213; -	(-0.2409; -	Placebo	
0.0180)	0.0649)	0.1889)	0.0313)		
-0.0473	0.0580	-0.2519	-0.0829	0.0532	0 - 1
(-0.1547;	(-0.0334;	(-0.3870; -	(-0.2083;	(-0.0157;	Solanezu
0.0602)	0.1494)	0.1168)	0.0425)	0.1220)	mab

Statistical significance: Drug vs. Placebo * p = 0.017; ** p < 0.0001; *** p = 0.0109

Heterogeneity $I^2 = 9.8\%$ [0.0%; 48.8%] p-value of Q statistics = 0.3493 in heterogeneity (within designs).

Table 1D. Bayesian Network Meta-Analysis: CDR-SB

Aducanuma b			
-0.1045 † (-0.2215, 0.0142)	Bapineuzu mab		
0.2022 (0.0361, 0.3628)	0.3063 (0.1493, 0.4552)	Donanemab	
0.0351 (-0.1328, 0.2049)	0.1397 † (-0.0191, 0.2954)	-0.1672 † (-0.3579, 0.033)	Lecanemab

-0.101	0.0037	-0.3026	-0.1358		
(-0.1961, -	(-0.0683,	(-0.4359, -	(-0.2771,	Placebo	
0.0073)	0.0736)	0.1642)	0.0032)		
-0.0499	0.0547	-0.2522	-0.0849	0.0511	Solonozu
(-0.1814,	(-0.0615,	(-0.4118, -	(-0.2558,	(-0.0387,	solaliezu
0.0762)	0.164)	0.0918)	0.0779)	0.1372)	mao

861

862

Table 2. League tables representing the results of random-effect model Frequentist 864 NMA and Bayesian NMA. The values in the tables represent Relative Risks (natural 865 logarithm) for tolerability (treatment discontinuations due to adverse events, A, B) and 866 for amyloid-related imaging abnormalities in form of cerebral edema (ARIA-E, C, D). 867 For each comparison, the number below 0 suggests that the drug in the column is safer 868 than the drug in the row. Darker red colors correspond to relatively higher risk. Bolded 869 numbers indicate statistical significance for Frequentist NMA (A, C), or strong evidence 870 in Bayesian NMA (**B**, **D**). The numbers in parentheses represent confidence intervals 871 (CIs) for Frequentist NMA (A, C), or credible intervals (CrIs) in Bayesian framework 872 (**B**, **D**). Dagger symbol (†) denotes when the interpretation differs significantly between 873 frequentist and Bayesian NMA results, indicating the uncertainty and lack of strong 874 evidence for a non-zero risk. 875

876

877

Aducanuma b						
0.2939 (-0.0956; 0.6835)	Bapineuzu mab					
-0.6066 (-1.0984; - 0.1148)	-0.9007 (-1.3042; - 0.4969)	Donanema b				
-0.1013 (-0.6663; 0.4639)	-0.3951 (-0.8855; 0.095)	0.5054 (-0.0695; 1.0802)	Lecanema b			
0.4973 * (0.1576; 0.837)	0.2033 † ** (0.0126; 0.3941)	1.1039 *** (0.7483; 1.4596)	0.5985 **** (0.1469; 1.0501)	Placebo		
0.4879 (0.0683; 0.9075)	0.194 (-0.1175; 0.5055)	1.0945 (0.6619; 1.5272)	0.5891 (0.0747; 1.1036)	-0.0093 (-0.2557; 0.237)	Solanezu mab	

Table 2A. Frequentist Network Meta-Analysis: Tolerability (TreatmentDiscontinuations due to Adverse Events)

Statistical significance: Drug vs. Placebo: * p = 0.0041; ** p = 0.0367; *** p < 0.0001; **** p = 0.0094

Heterogeneity $I^2 = 0\%$ [0.0%; 58.3%]; p-value of Q statistics = 0.9681 in heterogeneity (within designs).

Table 2B. Bayesian Network Meta-Analysis: Tolerability (Treatment Discontinuations due to Adverse Events)

Aducanuma b	
0.3021	Bapineuzu mab

(-0.1091, 0.7240) -0.6015 (-1.1231, -	-0.9037 (-1.3593, -	Donanema			
0.0708)	0.4631)	U			
-0.0962	-0.4024	0.5020			
(-0.7213,	(-0.9524,	(-0.1335,	Lecanemab		
0.5193)	0.1380)	1.1416)			
0.4985	0.1973 †	1.1006	0.5993		
(0.1378,	(-0.0195,	(0.7128,	(0.0926,	Placebo	
0.8585)	0.4092)	1.5001)	1.1026)		
0.4882	0.1879	1.0923	0.5932	-0.0093	C 1
(0.0415,	(-0.1697,	(0.6117,	(0.0163,	(-0.2870,	Solanezu
0.9542)	0.5445)	1.5767)	1.1629)	0.2734)	mab

 Table 2C. Frequentist Network Meta-Analysis: Total events of cerebral edema (ARIA-E)

Aducanuma					
b		_			
-0.1948	ם				
(-0.862;	Bapineuzu				
0.4723)	mab				
-0.0471	0.1477	Dononomo			
(-0.7302;	(-0.6694;	bonanema			
0.6361)	0.9648)	υ			
0.4015	0.5963	0.4486			
(-0.3838;	(-0.3077;	(-0.4674;	Lecanemab		
1.1866)	1.5004)	1.3646)			
2.4197 *	2.6145 *	2.4668 *	2.0182 *		
(2.0703;	(2.0462;	(1.8797;	(1.3151;	Placebo	
2.7691)	3.1828)	3.0539)	2.7213)		
2.5416	2.7365	2.5887	2.1402	0.122	Salar
(1.7171;	(1.798;	(1.6388;	(1.1145;	(-0.6249;	mah
3.3662)	3.6749)	3.5387)	3.1659)	0.8688)	mao

Statistical significance for Drug vs. Placebo: * p < 0.0001. Heterogeneity I² = 25.6% [0.0%; 63.1%]; p-value of Q statistics = 0.1997 in heterogeneity (within designs).

Table 2D. Bayesian Network Meta-Analysis: Total events of cerebral edema (ARIA-E)

Aducanuma b		
-0.2148 (-1.1414, 0.5154)	Bapineuzu mab	
-0.0492	0.1619	Donanema b

(-0.9452,	(-0.7384,				
0.8161)	1.2530)			_	
0.4018	0.6111	0.4492			
(-0.6774,	(-0.4272,	(-0.7444,	Lecanemab		
1.4623)	1.9019)	1.6828)			
2.4186	2.6376	2.4691	2.0176		
(1.9414,	(2.0373,	(1.7415,	(1.0681,	Placebo	
2.8973)	3.3955)	3.2262)	2.9953)		
2.5342	2.7477	2.5816	2.1355	0.1090	Solanozu
(1.4692,	(1.6868,	(1.3860,	(0.7887,	(-0.8196,	mah
3.4767)	3.8665)	3.6877)	3.3623)	0.9406)	mao

